

# Sofia Diana Merajver

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5661494/publications.pdf>

Version: 2024-02-01

206  
papers

12,267  
citations

22132

59  
h-index

30058

103  
g-index

215  
all docs

215  
docs citations

215  
times ranked

14976  
citing authors

#	ARTICLE	IF	CITATIONS
1	Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 77-102.	2.3	498
2	BRCA1 regulates human mammary stem/progenitor cell fate. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 1680-1685.	3.3	417
3	NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 9-20.	2.3	408
4	Somatic mutations in the BRCA1 gene in sporadic ovarian tumours. Nature Genetics, 1995, 9, 439-443.	9.4	380
5	Ten-Year Multi-Institutional Results of Breast-Conserving Surgery and Radiotherapy in BRCA1/2-Associated Stage I/II Breast Cancer. Journal of Clinical Oncology, 2006, 24, 2437-2443.	0.8	331
6	Oral Contraceptives and the Risk of Breast Cancer in BRCA1 and BRCA2 Mutation Carriers. Journal of the National Cancer Institute, 2002, 94, 1773-1779.	3.0	318
7	BRCA2 germline mutations in male breast cancer cases and breast cancer families. Nature Genetics, 1996, 13, 123-125.	9.4	315
8	NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 380-391.	2.3	314
9	Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis. Cancer Research, 2002, 62, 4854-9.	0.4	288
10	Targeting Breast Cancer Stem Cell State Equilibrium through Modulation of Redox Signaling. Cell Metabolism, 2018, 28, 69-86.e6.	7.2	284
11	Tamoxifen and Chemotherapy for Axillary Node-Negative, Estrogen Receptor-Negative Breast Cancer: Findings From National Surgical Adjuvant Breast and Bowel Project B-23. Journal of Clinical Oncology, 2001, 19, 931-942.	0.8	247
12	BRCA1 Mutation Analysis of 41 Human Breast Cancer Cell Lines Reveals Three New Deleterious Mutants. Cancer Research, 2006, 66, 41-45.	0.4	237
13	Nanoroughened Surfaces for Efficient Capture of Circulating Tumor Cells without Using Capture Antibodies. ACS Nano, 2013, 7, 566-575.	7.3	220
14	Persistent E-Cadherin Expression in Inflammatory Breast Cancer. Modern Pathology, 2001, 14, 458-464.	2.9	204
15	CCG-1423: a small-molecule inhibitor of RhoA transcriptional signaling. Molecular Cancer Therapeutics, 2007, 6, 2249-2260.	1.9	189
16	Characterization of RhoC Expression in Benign and Malignant Breast Disease. American Journal of Pathology, 2002, 160, 579-584.	1.9	187
17	Molecular biology of breast cancer metastasis Inflammatory breast cancer: clinical syndrome and molecular determinants. Breast Cancer Research, 2000, 2, 423-9.	2.2	180
18	Comparative analysis of circulating tumor DNA stability In K3EDTA, Streck, and CellSave blood collection tubes. Clinical Biochemistry, 2016, 49, 1354-1360.	0.8	175

#	ARTICLE	IF	CITATIONS
19	Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy. <i>Breast Cancer Research and Treatment</i> , 2010, 121, 389-398.	1.1	170
20	Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 153-162.	2.3	153
21	WISP3 is a novel tumor suppressor gene of inflammatory breast cancer. <i>Oncogene</i> , 2002, 21, 3172-3180.	2.6	141
22	Protein Kinase C $\mu$ Is a Predictive Biomarker of Aggressive Breast Cancer and a Validated Target for RNA Interference Anticancer Therapy. <i>Cancer Research</i> , 2005, 65, 8366-8371.	0.4	140
23	Single-cell Migration Chip for Chemotaxis-based Microfluidic Selection of Heterogeneous Cell Populations. <i>Scientific Reports</i> , 2015, 5, 9980.	1.6	137
24	RhoC GTPase Overexpression Modulates Induction of Angiogenic Factors in Breast Cells. <i>Neoplasia</i> , 2000, 2, 418-425.	2.3	132
25	Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer. <i>Clinical Cancer Research</i> , 2003, 9, 1666-72.	3.2	121
26	Identification of EZH2 as a Molecular Marker for a Precancerous State in Morphologically Normal Breast Tissues. <i>Cancer Research</i> , 2006, 66, 4095-4099.	0.4	120
27	Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 1.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 1326-1338.	2.3	119
28	Targeted Overexpression of EZH2 in the Mammary Gland Disrupts Ductal Morphogenesis and Causes Epithelial Hyperplasia. <i>American Journal of Pathology</i> , 2009, 175, 1246-1254.	1.9	114
29	Sentinel node biopsy prior to neoadjuvant chemotherapy. <i>American Journal of Surgery</i> , 2003, 186, 102-105.	0.9	113
30	Atorvastatin prevents RhoC isoprenylation, invasion, and metastasis in human melanoma cells. <i>Molecular Cancer Therapeutics</i> , 2003, 2, 941-8.	1.9	109
31	RhoC-GTPase is a Novel Tissue Biomarker Associated with Biologically Aggressive Carcinomas of the Breast. <i>Breast Cancer Research and Treatment</i> , 2005, 93, 101-110.	1.1	101
32	Breast conservation and prolonged chemotherapy for locally advanced breast cancer: the University of Michigan experience. <i>Journal of Clinical Oncology</i> , 1997, 15, 2873-2881.	0.8	100
33	The Role of Copper Suppression as an Antiangiogenic Strategy in Head and Neck Squamous Cell Carcinoma. <i>Laryngoscope</i> , 2001, 111, 696-701.	1.1	100
34	Histone Methyltransferase EZH2 Induces Akt-Dependent Genomic Instability and BRCA1 Inhibition in Breast Cancer. <i>Cancer Research</i> , 2011, 71, 2360-2370.	0.4	97
35	Mitogen activated protein kinase pathway is involved in RhoC GTPase induced motility, invasion and angiogenesis in inflammatory breast cancer. <i>Clinical and Experimental Metastasis</i> , 2002, 19, 301-311.	1.7	89
36	Overexpression of caveolin-1 and -2 in cell lines and in human samples of inflammatory breast cancer. <i>Breast Cancer Research and Treatment</i> , 2006, 95, 219-228.	1.1	87

#	ARTICLE	IF	CITATIONS
37	The Polycomb Group Protein EZH2 Impairs DNA Repair in Breast Epithelial Cells. <i>Neoplasia</i> , 2005, 7, 1011-1019.	2.3	86
38	A Hidden Feedback in Signaling Cascades Is Revealed. <i>PLoS Computational Biology</i> , 2008, 4, e1000041.	1.5	85
39	Tetrathiomolybdate inhibits angiogenesis and metastasis through suppression of the NFkappaB signaling cascade. <i>Molecular Cancer Research</i> , 2003, 1, 701-6.	1.5	85
40	Regulation of pancreatic cancer cell migration and invasion by RhoC GTPase and caveolin-1. <i>Molecular Cancer</i> , 2005, 4, 21.	7.9	84
41	WISP3 (CCN6) Is a Secreted Tumor-Suppressor Protein that Modulates IGF Signaling in Inflammatory Breast Cancer. <i>Neoplasia</i> , 2004, 6, 179-185.	2.3	82
42	A Phase II Trial of Tetrathiomolybdate After Surgery for Malignant Mesothelioma: Final Results. <i>Annals of Thoracic Surgery</i> , 2008, 86, 383-390.	0.7	77
43	Reversion of RhoC GTPase-induced inflammatory breast cancer phenotype by treatment with a farnesyl transferase inhibitor. <i>Molecular Cancer Therapeutics</i> , 2002, 1, 575-83.	1.9	77
44	Signaling properties of a covalent modification cycle are altered by a downstream target. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 10032-10037.	3.3	76
45	Radiotherapy and Antiangiogenic TM in Lung Cancer. <i>Neoplasia</i> , 2002, 4, 164-170.	2.3	75
46	Targeted Disruption of Protein Kinase C $\mu$ Reduces Cell Invasion and Motility through Inactivation of RhoA and RhoC GTPases in Head and Neck Squamous Cell Carcinoma. <i>Cancer Research</i> , 2006, 66, 9379-9384.	0.4	71
47	RhoA-GDP Regulates RhoB Protein Stability. <i>Journal of Biological Chemistry</i> , 2008, 283, 21588-21598.	1.6	71
48	Cancer-specific worry interference in women attending a breast and ovarian cancer risk evaluation program: impact on emotional distress and health functioning. <i>Psycho-Oncology</i> , 2001, 10, 349-360.	1.0	70
49	Multifaceted Role of Rho Proteins in Angiogenesis. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2005, 10, 291-298.	1.0	70
50	RhoC Induces Differential Expression of Genes Involved in Invasion and Metastasis in MCF10A Breast Cells. <i>Breast Cancer Research and Treatment</i> , 2004, 84, 3-12.	1.1	69
51	Genetic counseling forBRCA1/2: A randomized controlled trial of two strategies to facilitate the education and counseling process. <i>American Journal of Medical Genetics, Part A</i> , 2005, 134A, 66-73.	0.7	69
52	Phase II Trial of Tipifarnib plus Neoadjuvant Doxorubicin-Cyclophosphamide in Patients with Clinical Stage IIB-IIIC Breast Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 2942-2948.	3.2	69
53	Tetrathiomolybdate promotes tumor necrosis and prevents distant metastases by suppressing angiogenesis in head and neck cancer. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 1039-1045.	1.9	67
54	Pomegranate Fruit Extract Impairs Invasion and Motility in Human Breast Cancer. <i>Integrative Cancer Therapies</i> , 2009, 8, 242-253.	0.8	66

#	ARTICLE	IF	CITATIONS
55	Urban-rural differences in breast cancer incidence in Egypt (1999-2006). <i>Breast</i> , 2010, 19, 417-423.	0.9	64
56	Load-Induced Modulation of Signal Transduction Networks. <i>Science Signaling</i> , 2011, 4, ra67.	1.6	64
57	Suppression of Tumor Recurrence and Metastasis by a Combination of the PHSCN Sequence and the Antiangiogenic Compound Tetrathiomolybdate in Prostate Carcinoma. <i>Neoplasia</i> , 2002, 4, 373-379.	2.3	63
58	Comparative Analysis of Breast Cancer Phenotypes in African American, White American, and West Versus East African patients: Correlation Between African Ancestry and Triple-Negative Breast Cancer. <i>Annals of Surgical Oncology</i> , 2016, 23, 3843-3849.	0.7	63
59	IL-4/IL-13 Stimulated Macrophages Enhance Breast Cancer Invasion Via Rho-GTPase Regulation of Synergistic VEGF/CCL-18 Signaling. <i>Frontiers in Oncology</i> , 2019, 9, 456.	1.3	63
60	Construction of a transcription map surrounding the BRCA1 locus of human chromosome 17. <i>Genomics</i> , 1995, 25, 238-247.	1.3	62
61	RhoC GTPase Expression as a Potential Marker of Lymph Node Metastasis in Squamous Cell Carcinomas of the Head and Neck. <i>Clinical Cancer Research</i> , 2006, 12, 4485-4490.	3.2	61
62	Copper chelation in cancer therapy using tetrathiomolybdate: an evolving paradigm. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 541-548.	1.9	61
63	Characterization of the roles of RHOA and RHOB GTPases in invasion, motility, and matrix adhesion in inflammatory and aggressive breast cancers. <i>Cancer</i> , 2010, 116, 2768-2782.	2.0	61
64	Inhibition of CCN6 (Wnt-1-Induced Signaling Protein 3) Down-Regulates E-Cadherin in the Breast Epithelium through Induction of Snail and ZEB1. <i>American Journal of Pathology</i> , 2008, 172, 893-904.	1.9	60
65	RhoC Impacts the Metastatic Potential and Abundance of Breast Cancer Stem Cells. <i>PLoS ONE</i> , 2012, 7, e40979.	1.1	60
66	Control of Copper Status for Cancer Therapy. <i>Current Cancer Drug Targets</i> , 2005, 5, 543-549.	0.8	58
67	Hereditary Susceptibility for Triple Negative Breast Cancer Associated With Western Sub-Saharan African Ancestry. <i>Annals of Surgery</i> , 2019, 270, 484-492.	2.1	56
68	Urban-rural differences in breast cancer incidence by hormone receptor status across 6 years in Egypt. <i>Breast Cancer Research and Treatment</i> , 2010, 120, 149-160.	1.1	55
69	Updates on breast cancer genetics: Clinical implications of detecting syndromes of inherited increased susceptibility to breast cancer. <i>Seminars in Oncology</i> , 2016, 43, 528-535.	0.8	54
70	p38 Promotes Breast Cancer Cell Motility and Metastasis through Regulation of RhoC GTPase, Cytoskeletal Architecture, and a Novel Leading Edge Behavior. <i>Cancer Research</i> , 2011, 71, 6338-6349.	0.4	53
71	G-CSF secreted by mutant IDH1 glioma stem cells abolishes myeloid cell immunosuppression and enhances the efficacy of immunotherapy. <i>Science Advances</i> , 2021, 7, eabh3243.	4.7	53
72	TTK inhibition radiosensitizes basal-like breast cancer through impaired homologous recombination. <i>Journal of Clinical Investigation</i> , 2020, 130, 958-973.	3.9	53

#	ARTICLE	IF	CITATIONS
73	Increased risk for distant metastasis in patients with familial early-stage breast cancer and high EZH2 expression. <i>Breast Cancer Research and Treatment</i> , 2012, 132, 429-437.	1.1	52
74	Breast Cancer Risk Reduction, Version 2.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 880-915.	2.3	52
75	Clinical and Epidemiologic Profile of Breast Cancer in Tanzania. <i>Breast Disease</i> , 2010, 31, 33-41.	0.4	51
76	Characterization of EZH1, a Human Homolog of Drosophila Enhancer of zeste near BRCA1. <i>Genomics</i> , 1996, 37, 161-171.	1.3	49
77	Factors related to incomplete treatment of breast cancer in Kumasi, Ghana. <i>Breast</i> , 2014, 23, 821-828.	0.9	49
78	Cancer classification in the genomic era: five contemporary problems. <i>Human Genomics</i> , 2015, 9, 27.	1.4	48
79	Breast cancer characteristics at diagnosis and survival among Arab-American women compared to European-American and African-American women. <i>Breast Cancer Research and Treatment</i> , 2009, 114, 339-346.	1.1	46
80	Inflammatory and non-inflammatory breast cancer survival by socioeconomic position in the Surveillance, Epidemiology, and End Results database, 1990-2008. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 1257-1268.	1.1	46
81	Effects of postpartum mobile phone-based education on maternal and infant health in Ecuador. <i>International Journal of Gynecology and Obstetrics</i> , 2016, 134, 93-98.	1.0	43
82	Antiangiogenic tetrathiomolybdate enhances the efficacy of doxorubicin against breast carcinoma. <i>Molecular Cancer Therapeutics</i> , 2003, 2, 617-22.	1.9	43
83	On the Role of Cell Signaling Models in Cancer Research. <i>Cancer Research</i> , 2009, 69, 400-402.	0.4	42
84	A pilot trial of the anti-angiogenic copper lowering agent tetrathiomolybdate in combination with irinotecan, 5-fluorouracil, and leucovorin for metastatic colorectal cancer. <i>Investigational New Drugs</i> , 2009, 27, 159-165.	1.2	42
85	Use of Cancer Genetics Services in African-American Young Breast Cancer Survivors. <i>American Journal of Preventive Medicine</i> , 2016, 51, 427-436.	1.6	42
86	Cancer Therapy With Tetrathiomolybdate: Antiangiogenesis by Lowering Body Copper—A Review. <i>Integrative Cancer Therapies</i> , 2002, 1, 327-337.	0.8	41
87	Macrophages Enhance Migration in Inflammatory Breast Cancer Cells via RhoC GTPase Signaling. <i>Scientific Reports</i> , 2016, 6, 39190.	1.6	41
88	Triple-Negative Breast Cancer in Ghanaian Women: The Korle Bu Teaching Hospital Experience. <i>Breast Journal</i> , 2015, 21, 627-633.	0.4	40
89	High-content fluorescence imaging with the metabolic flux assay reveals insights into mitochondrial properties and functions. <i>Communications Biology</i> , 2020, 3, 271.	2.0	40
90	Detection of Epstein-Barr Virus in Rapidly Growing Fibroadenomas of the Breast in Immunosuppressed Hosts. <i>Modern Pathology</i> , 2002, 15, 759-764.	2.9	39

#	ARTICLE	IF	CITATIONS
91	Engineered Tools to Study Intercellular Communication. <i>Advanced Science</i> , 2021, 8, 2002825.	5.6	39
92	Treatment of infertility does not increase the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation. <i>Fertility and Sterility</i> , 2016, 105, 781-785.	0.5	38
93	High Proportion of Inflammatory Breast Cancer in the Population-Based Cancer Registry of Gharbiah, Egypt. <i>Breast Journal</i> , 2009, 15, 432-434.	0.4	37
94	Long Signaling Cascades Tend to Attenuate Retroactivity. <i>Biophysical Journal</i> , 2011, 100, 1617-1626.	0.2	37
95	Global mental health: Global strengths and strategies. <i>Asian Journal of Psychiatry</i> , 2011, 4, 165-171.	0.9	36
96	Breast Cancer Risk Reduction. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2010, 8, 1112-1146.	2.3	34
97	Clinical predictors of long-term survival in HER2-positive metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 155, 589-595.	1.1	34
98	Multisite Phosphorylation Provides an Effective and Flexible Mechanism for Switch-Like Protein Degradation. <i>PLoS ONE</i> , 2010, 5, e14029.	1.1	34
99	Breast cancers utilize hypoxic glycogen stores via PYGB, the brain isoform of glycogen phosphorylase, to promote metastatic phenotypes. <i>PLoS ONE</i> , 2019, 14, e0220973.	1.1	33
100	Disparities in genetic services utilization in a random sample of young breast cancer survivors. <i>Genetics in Medicine</i> , 2019, 21, 1363-1370.	1.1	33
101	RhoC Expression and Head and Neck Cancer Metastasis. <i>Molecular Cancer Research</i> , 2009, 7, 1771-1780.	1.5	32
102	Promoters of and barriers to cervical cancer screening in a rural setting in Tanzania. <i>International Journal of Gynecology and Obstetrics</i> , 2013, 123, 221-225.	1.0	32
103	A platform for artificial intelligence based identification of the extravasation potential of cancer cells into the brain metastatic niche. <i>Lab on A Chip</i> , 2019, 19, 1162-1173.	3.1	32
104	CCN6 (WISP3) as a New Regulator of the Epithelial Phenotype in Breast Cancer. <i>Cells Tissues Organs</i> , 2007, 185, 95-99.	1.3	31
105	Traditional Herbalists and Cancer Management in Kumasi, Ghana. <i>Journal of Cancer Education</i> , 2012, 27, 573-579.	0.6	31
106	Picosecond-resolution fluorescence lifetime imaging microscopy: a useful tool for sensing molecular interactions in vivo via FRET. <i>Optics Express</i> , 2007, 15, 18220.	1.7	30
107	Incidence and survival of inflammatory breast cancer between 1973 and 2015 in the SEER database. <i>Breast Cancer Research and Treatment</i> , 2021, 185, 229-238.	1.1	30
108	RhoC GTPase Is a Potent Regulator of Glutamine Metabolism and N-Acetylaspartate Production in Inflammatory Breast Cancer Cells. <i>Journal of Biological Chemistry</i> , 2016, 291, 13715-13729.	1.6	29

#	ARTICLE	IF	CITATIONS
109	Breast Cancer in Ghana: Demonstrating the Need for Population-Based Cancer Registries in Low- and Middle-Income Countries. <i>Journal of Global Oncology</i> , 2017, 3, 765-772.	0.5	29
110	Antiangiogenic Tetrathiomolybdate Protects against Her2/neu-Induced Breast Carcinoma by Hypoplastic Remodeling of the Mammary Gland. <i>Clinical Cancer Research</i> , 2009, 15, 7441-7446.	3.2	28
111	Characterizing Breast Cancer in a Population with Increased Prevalence of Triple-Negative Breast Cancer: Androgen Receptor and ALDH1 Expression in Ghanaian Women. <i>Annals of Surgical Oncology</i> , 2015, 22, 3831-3835.	0.7	27
112	Association of Inflammatory and Noninflammatory Breast Cancer with Socioeconomic Characteristics in the Surveillance, Epidemiology, and End Results Database, 2000â€“2007. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 155-165.	1.1	25
113	Pre-operative chemoradiation followed by post-operative adjuvant therapy with tetrathiomolybdate, a novel copper chelator, for patients with resectable esophageal cancer. <i>Investigational New Drugs</i> , 2013, 31, 435-442.	1.2	25
114	UM-164: A Potent c-Src/p38 Kinase Inhibitor with <i>In Vivo</i> Activity against Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 5087-5096.	3.2	25
115	Preclinical Development of a Bifunctional Cancer Cell Homing, PKCÎµ Inhibitory Peptide for the Treatment of Head and Neck Cancer. <i>Cancer Research</i> , 2009, 69, 5829-5834.	0.4	24
116	Tracking the tumor invasion front using long-term fluidic tumoroid culture. <i>Scientific Reports</i> , 2017, 7, 10784.	1.6	24
117	Individual and family characteristics associated with <i>BRCA1/2</i> genetic testing in high-risk families. <i>Psycho-Oncology</i> , 2013, 22, 1336-1343.	1.0	23
118	Characterizing breast cancer treatment pathways in Kumasi, Ghana from onset of symptoms to final outcome: Outlook towards cancer control. <i>Breast Disease</i> , 2014, 34, 139-149.	0.4	23
119	Nanoroughened adhesion-based capture of circulating tumor cells with heterogeneous expression and metastatic characteristics. <i>BMC Cancer</i> , 2016, 16, 614.	1.1	23
120	Raman spectroscopic study of the conformational order in hexadecane solutions. <i>Journal of Chemical Physics</i> , 1981, 74, 5341-5346.	1.2	22
121	Characterizing inflammatory breast cancer among Arab Americans in the California, Detroit and New Jersey Surveillance, Epidemiology and End Results (SEER) registries (1988â€“2008). <i>SpringerPlus</i> , 2013, 2, 3.	1.2	22
122	Breast Cancer and African Ancestry: Lessons Learned at the 10-Year Anniversary of the Ghana-Michigan Research Partnership and International Breast Registry. <i>Journal of Global Oncology</i> , 2016, 2, 302-310.	0.5	22
123	Biophysical Phenotyping and Modulation of ALDH+ Inflammatory Breast Cancer Stem-Like Cells. <i>Small</i> , 2019, 15, e1802891.	5.2	21
124	Molecular epidemiologic features of inflammatory breast cancer: a comparison between Egyptian and US patients. <i>Breast Cancer Research and Treatment</i> , 2008, 112, 141-147.	1.1	20
125	Using a state cancer registry to recruit young breast cancer survivors and high-risk relatives: protocol of a randomized trial testing the efficacy of a targeted versus a tailored intervention to increase breast cancer screening. <i>BMC Cancer</i> , 2013, 13, 97.	1.1	20
126	Mechanotransduction-Induced Reversible Phenotypic Switching in Prostate Cancer Cells. <i>Biophysical Journal</i> , 2017, 112, 1236-1245.	0.2	20



#	ARTICLE	IF	CITATIONS
127	An anticopper antiangiogenic approach for advanced cancer in spontaneously occurring tumors using tetrathiomolybdate: A pilot study in a canine animal model. <i>Journal of Trace Elements in Experimental Medicine</i> , 2004, 17, 9-20.	0.8	19
128	Analysis of RhoC expression and lymphovascular emboli in inflammatory vs non-inflammatory breast cancers in Egyptian patients. <i>Breast</i> , 2009, 18, 55-59.	0.9	19
129	Xenoestrogens may be the cause of high and increasing rates of hormone receptor positive breast cancer in the world. <i>Medical Hypotheses</i> , 2009, 72, 652-656.	0.8	19
130	Public and Professional Educational Needs for Downstaging Breast Cancer in Egypt. <i>Journal of Cancer Education</i> , 2012, 27, 149-155.	0.6	19
131	Assessment of diagnosis of inflammatory breast cancer cases at two cancer centers in Egypt and Tunisia. <i>Cancer Medicine</i> , 2013, 2, 178-184.	1.3	19
132	Trends in Breast Cancer Stage and Mortality in Michigan (1992-2009) by Race, Socioeconomic Status, and Area Healthcare Resources. <i>PLoS ONE</i> , 2013, 8, e61879.	1.1	19
133	Development of a Web-based Family Intervention for BRCA Carriers and Their Biological Relatives: Acceptability, Feasibility, and Usability Study. <i>JMIR Cancer</i> , 2018, 4, e7.	0.9	19
134	Establishing effective registration systems in resource-limited settings: cancer registration in Kumasi, Ghana. <i>Journal of Registry Management</i> , 2013, 40, 70-7.	0.1	19
135	Genetic Determinants of Aggressive Breast Cancer. <i>Annual Review of Medicine</i> , 2008, 59, 199-212.	5.0	18
136	Breast Cancer by Age at Diagnosis in the Gharbiah, Egypt, Population-Based Registry Compared to the United States Surveillance, Epidemiology, and End Results Program, 2004-2008. <i>BioMed Research International</i> , 2015, 2015, 1-9.	0.9	18
137	Recruiting families at risk for hereditary breast and ovarian cancer from a statewide cancer registry: a methodological study. <i>Cancer Causes and Control</i> , 2017, 28, 191-201.	0.8	18
138	Rho Proteins and Cell-Matrix Interactions in Cancer. <i>Cells Tissues Organs</i> , 2007, 185, 100-103.	1.3	17
139	Smart Nanoparticles Enhance the Cytoplasmic Delivery of Anti-RhoC Silencing RNA and Inhibit the Migration and Invasion of Aggressive Breast Cancer Cells. <i>Molecular Pharmaceutics</i> , 2015, 12, 2406-2417.	2.3	17
140	The Impact of Nathan Mantel's The Detection of Disease Clustering and a Generalized Regression Approach. <i>Cancer Research</i> , 2016, 76, 2495-2496.	0.4	17
141	Absence of CHEK2*1100delC mutation in families with hereditary breast cancer in North America. <i>Cancer Genetics and Cytogenetics</i> , 2010, 202, 136-140.	1.0	16
142	Direct antitumour activity of zoledronic acid: preclinical and clinical data. <i>Clinical and Translational Oncology</i> , 2011, 13, 148-155.	1.2	16
143	Knowledge Gained After a Brief CME Module on Breast Cancer Diagnosis. <i>Journal of Cancer Education</i> , 2006, 21, 169-174.	0.6	16
144	A YAC-, P1-, and cosmid-based physical Map of the BRCA1 region on chromosome 17q21. <i>Genomics</i> , 1995, 25, 264-273.	1.3	15

#	ARTICLE	IF	CITATIONS
145	A Comparison of Criteria to Identify Inflammatory Breast Cancer Cases from Medical Records and the Surveillance, Epidemiology and End Results Data base, 2007-2009. <i>Breast Journal</i> , 2014, 20, 185-191.	0.4	15
146	Scientific Summary from the Morgan Welch MD Anderson Cancer Center Inflammatory Breast Cancer (IBC) Program 10th Anniversary Conference. <i>Journal of Cancer</i> , 2017, 8, 3607-3614.	1.2	15
147	Risk Factors for Chronic Mastitis in Morocco and Egypt. <i>International Journal of Inflammation</i> , 2013, 2013, 1-10.	0.9	14
148	Heterogeneity at the invasion front of triple negative breast cancer cells. <i>Scientific Reports</i> , 2020, 10, 5781.	1.6	14
149	Norstictic Acid Is a Selective Allosteric Transcriptional Regulator. <i>Journal of the American Chemical Society</i> , 2021, 143, 9297-9302.	6.6	13
150	Modulation of Angiogenesis for Cancer Prevention: Strategies Based On Antioxidants and Copper Deficiency. <i>Current Pharmaceutical Design</i> , 2007, 13, 3584-3590.	0.9	12
151	Surveillance for cancer recurrence in long-term young breast cancer survivors randomly selected from a statewide cancer registry. <i>Breast Cancer Research and Treatment</i> , 2018, 169, 141-152.	1.1	12
152	Androgen Receptor and ALDH1 Expression Among Internationally Diverse Patient Populations. <i>Journal of Global Oncology</i> , 2018, 4, 1-8.	0.5	12
153	Synergistic inhibition of aggressive breast cancer cell migration and invasion by cytoplasmic delivery of anti-RhoC silencing RNA and presentation of EPPT1 peptide on $\alpha$ - $\omega$ -smart $\alpha$ -particles. <i>Journal of Controlled Release</i> , 2018, 289, 79-93.	4.8	12
154	A Randomized Phase IIb Study of Low-dose Tamoxifen in Chest-irradiated Cancer Survivors at Risk for Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 967-974.	3.2	12
155	Familial breast cancer. Approaching the isolation of a susceptibility gene. <i>Cancer</i> , 1994, 74, 1013-1020.	2.0	11
156	Androgen receptor polyglutamine tract length in Egyptian male breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2011, 129, 575-581.	1.1	11
157	Inferring the Effects of Honokiol on the Notch Signaling Pathway in SW480 Colon Cancer Cells. <i>Cancer Informatics</i> , 2014, 13s5, CIN.S14060.	0.9	11
158	Chronic Mastitis in Egypt and Morocco: Differentiating between Idiopathic Granulomatous Mastitis and IgG4-Related Disease. <i>Breast Journal</i> , 2016, 22, 501-509.	0.4	10
159	Clinico-pathologic and mammographic characteristics of inflammatory and non-inflammatory breast cancer at six centers in North Africa. <i>Breast Cancer Research and Treatment</i> , 2019, 176, 407-417.	1.1	10
160	Ultrahigh-molecular-weight polyethylene: Raman spectroscopic study of melt anisotropy. <i>Journal of Polymer Science, Part B: Polymer Physics</i> , 1986, 24, 99-110.	2.4	9
161	Deleterious CHEK2 1100delC and L303X mutants identified among 38 human breast cancer cell lines. <i>Breast Cancer Research and Treatment</i> , 2009, 113, 285-291.	1.1	9
162	Clinical characteristics, HIV status, and molecular biomarkers in squamous cell carcinoma of the conjunctiva in Ghana. <i>Health Science Reports</i> , 2019, 2, e108.	0.6	9

#	ARTICLE	IF	CITATIONS
163	Intermolecular interactions and Fermi resonance in methylene groups. <i>Journal of Chemical Physics</i> , 1982, 76, 3344-3345.	1.2	8
164	Spectroscopic study of $\hat{1}\pm$ - and $\hat{1}^2$ -phase isotactic polypropylene and of atactic polypropylene in solution. <i>Journal of Polymer Science, Polymer Physics Edition</i> , 1985, 23, 2043-2057.	1.0	8
165	The role of cognitive appraisal and worry in BRCA1/2 testing decisions among a clinic population. <i>Psychology and Health</i> , 2007, 22, 719-736.	1.2	8
166	One-Hit Effects and Cancer. <i>Cancer Prevention Research</i> , 2010, 3, 12-15.	0.7	8
167	Reliability of medical records in diagnosing inflammatory breast cancer in Egypt. <i>BMC Research Notes</i> , 2017, 10, 126.	0.6	8
168	Metastatic Dedifferentiated Chordoma With Elevated $\hat{1}^2$ -hCG. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2002, 25, 274-276.	0.6	7
169	Shock wave impact on the viability of MDA-MB-231 cells. <i>PLoS ONE</i> , 2020, 15, e0234138.	1.1	7
170	Multiethnic PDX models predict a possible immune signature associated with TNBC of African ancestry. <i>Breast Cancer Research and Treatment</i> , 2021, 186, 391-401.	1.1	7
171	Retroactive Signaling in Short Signaling Pathways. <i>PLoS ONE</i> , 2012, 7, e40806.	1.1	7
172	The changing pattern of ano-rectal cancer, squamous cell carcinoma of the eye, and Hodgkin's lymphoma as non-AIDS-defining cancers, by HIV status, in Tanzania over 11 years (2002-2012): a retrospective case-report study. <i>Infectious Agents and Cancer</i> , 2014, 9, 42.	1.2	6
173	Risk factors for inflammatory and non-inflammatory breast cancer in North Africa. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 543-558.	1.1	6
174	Inflammatory breast cancer: what are the treatment options?. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 2987-2997.	0.9	5
175	Survival of Inflammatory Breast Cancer Patients Compared to Non-inflammatory Breast Cancer Patients in Egypt. <i>Breast Journal</i> , 2011, 17, 545-547.	0.4	5
176	Molecular determinants of drug response in TNBC cell lines. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 337-347.	1.1	5
177	Impact of between-tissue differences on pan-cancer predictions of drug sensitivity. <i>PLoS Computational Biology</i> , 2021, 17, e1008720.	1.5	5
178	Initial Findings from a High Genetic Risk Prostate Cancer Clinic. <i>Urology</i> , 2021, 156, 96-103.	0.5	5
179	Quantifying the Brain Metastatic Tumor Micro-Environment using an Organ-On-A Chip 3D Model, Machine Learning, and Confocal Tomography. <i>Journal of Visualized Experiments</i> , 2020, , .	0.2	5
180	Genetic Literacy and Communication of Genetic Information in Families Concerned with Hereditary Breast and Ovarian Cancer: A Cross-Study Comparison in Two Countries and within a Timeframe of More Than 10 Years. <i>Cancers</i> , 2021, 13, 6254.	1.7	5

#	ARTICLE	IF	CITATIONS
181	Random-walk model of the phase transition of hydrocarbon chains on a lattice. <i>Physical Review A</i> , 1981, 23, 897-907.	1.0	4
182	Implementation of INHERET, an Online Family History and Cancer Risk Interpretation Program for Primary Care and Specialty Clinics. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 63-70.	2.3	4
183	Characterization of hexadecanoic acid perdeuterated from carbon eight to carbon sixteen: a novel conformational probe for amphipathic systems. <i>Chemistry and Physics of Lipids</i> , 1981, 29, 379-384.	1.5	3
184	Breast Cancer Risk Assessment: A Guide for Clinicians Using the NCCN Breast Cancer Risk Reduction Guidelines. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2003, 1, 297-301.	2.3	3
185	Rethinking the war on cancer: multidisciplinary collaborations between biologists and physical scientists. <i>Future Oncology</i> , 2012, 8, 339-341.	1.1	3
186	Genetic Testing and Surveillance of Young Breast Cancer Survivors and Blood Relatives: A Cluster Randomized Trial. <i>Cancers</i> , 2020, 12, 2526.	1.7	3
187	RhoC Modulates Cell Junctions and Type I Interferon Response in Aggressive Breast Cancers. <i>Frontiers in Oncology</i> , 2021, 11, 712041.	1.3	3
188	Global comparative healthcare effectiveness research: evaluating sustainable programmes in low & middle resource settings. <i>Indian Journal of Medical Research</i> , 2013, 137, 494-501.	0.4	3
189	Theory of the conformational order of single component sphingomyelin bilayers. <i>Journal of Theoretical Biology</i> , 1981, 93, 737-755.	0.8	2
190	Transcript identification in the BRCA1 candidate region. <i>Breast Cancer Research and Treatment</i> , 1995, 33, 115-124.	1.1	2
191	Low-Dose Tamoxifen (LDTam) As a Breast Cancer (BC) Risk-Reduction Strategy in Lymphoma Survivors Exposed to Chest Radiation Therapy (RT) during Adolescence/Young Adulthood - a Randomized, Placebo-Controlled Double Blinded Phase IIb Trial. <i>Blood</i> , 2019, 134, 2843-2843.	0.6	2
192	MEK is a promising target in the basal subtype of bladder cancer. <i>Oncotarget</i> , 2020, 11, 3921-3932.	0.8	2
193	Bisphosphonates in Breast Cancer: From Metastasis to Prevention. <i>Current Breast Cancer Reports</i> , 2010, 2, 222-230.	0.5	1
194	Breast cancer screening recommendations: dynamic extrapolation of limited data. <i>Breast Cancer Research and Treatment</i> , 2010, 121, 143-146.	1.1	1
195	Making the case for integrated assessments of the biological, social, and system determinants of treatment for breast cancer to understand and improve outcomes in patients everywhere. <i>Current Medical Research and Opinion</i> , 2012, 28, 415-417.	0.9	1
196	WISP3 is a novel tumor suppressor gene of inflammatory breast cancer. , 0, .		1
197	Insights into the modular design of kinase inhibitors and application to Abl and Axl. <i>RSC Medicinal Chemistry</i> , 2022, 13, 64-71.	1.7	1
198	Differences in Reliability of Reproductive History Recall Among Women in North Africa. <i>The International Electronic Journal of Health Education</i> , 2009, 12, 150-161.	0.5	1

#	ARTICLE	IF	CITATIONS
199	Conquering the challenges of genotypic and phenotypic tumor heterogeneity to realize the promise of personalized cancer therapy: the role of academia. Transactions of the American Clinical and Climatological Association, 2017, 128, 169-179.	0.9	1
200	Introduction on Angiogenesis in Breast Cancer. Journal of Mammary Gland Biology and Neoplasia, 2005, 10, 281-282.	1.0	0
201	Response to Comment on "Load-Induced Modulation of Signal Transduction Networks™: Reconciling Ultrasensitivity with Bifunctionality", Science Signaling, 2012, 5, .	1.6	0
202	Development of an Enhanced-Throughput Radial Cell Migration Device. SLAS Technology, 2021, 26, 200-208.	1.0	0
203	Shock wave impact on the viability of MDA-MB-231 cells. , 2020, 15, e0234138.		0
204	Shock wave impact on the viability of MDA-MB-231 cells. , 2020, 15, e0234138.		0
205	Shock wave impact on the viability of MDA-MB-231 cells. , 2020, 15, e0234138.		0
206	Shock wave impact on the viability of MDA-MB-231 cells. , 2020, 15, e0234138.		0